Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2 by Mansourian, Marjan et al.
EXCLI Journal 2018;17:45-56 – ISSN 1611-2156 
Received: November 27, 2017, accepted: December 22, 2017, published: January 08, 2018 
 
 
45 
Original article: 
DIFFERENT EFFECTS OF METFORMIN AND INSULIN ON  
PRIMARY AND SECONDARY CHEMOPREVENTION OF  
COLORECTAL ADENOMA IN DIABETES TYPE 2:  
TRADITIONAL AND BAYESIAN META-ANALYSIS 
 
Marjan Mansourian1, Raheleh Karimi1, 2, Golnaz Vaseghi3* 
 
1  Epidemiology and Biostatistics Department, School of Health, Isfahan University of  
Medical Sciences, Isfahan, Iran 
2 Student Research Committee, School of Health, Isfahan University of Medical Sciences, 
Isfahan, Iran 
3 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan  
University of Medical Sciences, Isfahan, Iran 
 
* Corresponding author: G. Vaseghi, Isfahan Cardiovascular Research Center,  
Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; 
E-mail: golnazvaseghi@yahoo.com 
 
 
http://dx.doi.org/10.17179/excli2017-993 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/4.0/). 
 
ABSTRACT 
Metformin and insulin differently affect the risk of colon cancer in type 2 diabetic patients, however their effects 
on colon adenoma is not clear. PubMed, ISI, Scopus and Cochrane databases were searched for studies reporting. 
The outcomes were total adenoma; advanced adenoma and recurrent adenoma. Traditional and Bayesian meta-
analysis were conducted via random-effects models. Odds ratios (OR) with 95 % confidence intervals (CIs) / or 
credible intervals (CrI) were used to describe the ratio of different events. A random-effects model described by 
DerSimonian and Laird was performed, when significant between-study heterogeneity existed. Alternatively, an 
inverse variance fixed effects model was used, when there was no significant heterogeneity across studies. The 
potential publication bias was assessed with funnel plot, Egger and Begg's regression asymmetry tests. Moreover, 
“trim and fill” procedure was used to assess the possible effect of publication bias. For metformin intake, 11 studies 
(51991 patients) were included. The results showed that metformin significantly decreased the risk of advance 
adenoma (OR= 0.51, p< 0.001). The risk of total adenoma was not associated with metformin use (OR= 0.86, 
p=0.274), and metformin did not affect the risk of adenoma recurrence (OR= 0.89, p=0.137). Five studies (2678 
patients) were included in the analysis to determine the effect of insulin therapy. Insulin significantly increased 
the risk of colorectal adenoma (OR= 1.43, p=0.002). These findings indicate that metformin has no protective 
effect on total and recurrent adenoma, whilst it significantly reduces the risk of advanced adenoma, but insulin 
increases the risk of total adenoma.  
 
Keywords: metformin, insulin, adenoma, colonic polyps, diabetes mellitus type 2, meta-analysis  
 
 
INTRODUCTION 
Colorectal cancer (CRC) is one of the 
most common cancer globally, it has been 
shown that the incidence of CRC has been in-
creasing worldwide (Torre et al., 2015). Col-
orectal adenomas are relatively prone to de-
velop into colorectal carcinoma (Morson, 
1974). Accordingly, therapies that lessen ad-
enoma recurrence may additionally lessen 
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both CRC risk and the necessity for colonos-
copy (Lieberman et al., 2005). One of the 
well-known risk factor for CRC is type 2 dia-
betes; hyperinsulinemia caused by insulin re-
sistance, influences the incidence of CRC 
(Weiderpass et al., 1997). However, exoge-
nous insulin leads to higher concentration of 
systemic hyper-insulinemia state compare to 
endogenous hyper-insulinemia (Genuth, 
1990). Recent studies have reported a signifi-
cant increase in risk of CRC and colorectal 
adenomas, respectively, among patients with 
type 2 diabetes on insulin therapy compared 
to non-insulin users (Chung et al., 2008; Yang 
et al., 2004), but the data are still conflicting. 
Metformin is another potent anti-hyper-
glycemic drug. It can decrease hyperinsuline-
mia, increase insulin sensitivity (Ashokkumar 
et al., 2006) and reduce blood glucose con-
centrations (Viollet et al., 2012). Metformin 
also activates liver kinase B1-dependent 
AMP-activated protein kinase (AMPK) in the 
liver, activated AMPK inhibits the prolifera-
tion and growth of cells by inhibiting mam-
malian target of rapamycin (Sarbassov et al., 
2005).  
Some animal studies have revealed that 
metformin prevents the proliferation of co-
lonic epithelial cells (Tomimoto et al., 2008). 
A few scientists showed that metformin might 
be a potential defensive factor of colorectal 
adenomas and colorectal disease in T2DM pa-
tients (Cho et al., 2014; Chung et al., 2008; 
Jain et al., 2016; Kanadiya et al., 2013; Kim 
et al., 2015). However, some different inves-
tigations found no connection between met-
formin treatment and colorectal adenomas or 
colorectal malignancy (Eddi et al., 2012; 
Lewis et al., 2007), thus the results were still 
inconsistent. Inconsistencies in these results 
might cause by variations in study style, pop-
ulations, or totally different applied mathe-
matics strategies. Some researchers have per-
formed meta-analysis to assess the link be-
tween metformin use and adenoma risk (Jung 
et al., 2017). It has been suggested that CRC 
risk among diabetes may vary with the type of 
treatment (Eddi et al., 2012). So we conduct 
this study to explore associations between 
metformin or insulin use and adenomas risk, 
the impact of metformin on prevention of sec-
ondary adenoma, and to investigate if differ-
ent treatments affect the risk of adenoma. 
 
MATERIAL AND METHODS 
Search strategy  
A systematic search of the online data-
bases PubMed, ISI, Scopus, and Cochrane 
Collaboration up to January 2017 without any 
restrictions was conducted to find published 
articles. Search terms were: (“Metformin”) 
OR (“Insulin”) AND (“Adenoma*” OR “Col-
orectal adenoma*” OR “Colon polyp*”OR 
“Colon adenoma *” OR “Colorectal polyps” 
OR “Advanced adenoma*”OR “Recurrent 
adenoma*” OR “Neoplasms”) AND (“Diabe-
tes Mellitus, Type 2”OR“type 2diabetes”). 
All eligible studies were reviewed, and their 
bibliographies were checked for other rele-
vant publications. For carrying out and report-
ing meta-analyses of observational studies, 
the standard criteria were followed.  
 
Statistical analysis 
Agreement on the selection of studies be-
tween the two reviewers was evaluated by the 
kappa coefficient. Meta-analysis was per-
formed using both traditional and Bayesian 
meta-analysis. When the two methods pro-
duced different results, the results of Bayesian 
method was approved. The effect sizes were 
calculated based on total colorectal adenoma, 
advanced adenoma, and recurrence of ade-
noma in diabetic metformin users and also for 
the total colorectal adenomain diabetic insulin 
users compared with controls. Briefly, the 
odds ratio (OR, 95 % confidence intervals 
(CIs) / or credible intervals (CrI)) were used 
to describe the ratio of different events occur-
ring in diabetic patients. An Inverse Variance 
fixed effects model was used to calculate the 
pooled effect measure. Otherwise, the random 
effects model described by Der Simonian and 
Laird (1986) was applied if there was evi-
dence of heterogeneity. 
Heterogeneity between studies was as-
sessed by I2 statistic and Cochrane’s Q-statis-
tic (Higgins et al., 2003). 
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In the presence of significant statistical 
heterogeneity, apart from the random-effects 
model, sensitivity analyses were performed to 
evaluate the consistency of our results. First-
ly, to evaluate any possible excessive influ-
ence of a single study, we examined whether 
the exclusion of this study substantially al-
tered the magnitude or heterogeneity of the 
summary estimate. This was achieved by re-
peating the meta-analyses with exclusion of 
each individual study one at a time, to assess 
the overall effect of the exclusion on the 
pooled Ors (Sutton et al., 2000a).Secondly, 
subgroup analyses were performed by strati-
fying meta-analysis upon different factors 
that could potentially influence the results. 
These factors were established a priori to the 
analysis. We further explored heterogeneity 
by performing meta-regression analyses 
(method of moments) (Borenstein et al., 
2009). 
In Bayesian hierarchical random-effects 
models (Best, 2005; Sutton et al., 2000b), the 
first 10,000 iterations were discarded and re-
sults were reported as the posterior mean 
(OR) with 95 % (CrI) on the basis of a further 
100,000 iterations.  
For the mean OR outcome, a normal prior 
with a large variance N(0,105), as a vague 
prior, is placed upon the pooled effect size. As 
our meta-analysis include small numbers of 
studies, there was little information in the 
likelihood regarding the estimation of the be-
tween study variance parameter. In this situa-
tion. The prior can be influential in the analy-
sis (Lambert et al., 2005). In this regard, we 
defined Gamma distribution and Hulf-normal 
as an informative prior, in addition of using 
Uniform distribution for between study vari-
ance. 
The likelihood of publication bias was as-
sessed by constructing funnel plots (not 
shown), which were obtained by plotting the 
log ORs vs. SE of individual studies. Their 
symmetry was estimated by Egger's regres-
sion test and the Begg and Mazumdar ad-
justed rank correlation test (Begg and 
Mazumdar, 1994; Copas and Shi, 2001; Egger 
et al., 1997). P values below 0.05 were inter-
preted as statistically significant, and the trim 
and fill method was used to further assess the 
possible effect of publication bias on the re-
sults of our meta-analysis (Duval and 
Tweedie, 2000).The results of analysis was 
performed by Stata version 14 and Open 
BUGS version 3.2.3. 
 
RESULTS 
Search results and study characteristics  
A comprehensive literature review search, 
up to January 2017 was carried out (see Fig-
ure 1), overall, 652 potentially eligible studies 
were comforted to the inclusion criteria of this 
meta-analysis according metformin-treated 
diabetic patients. After excluding duplicates, 
we selected 365 records. Two hundred and 
eighty-seven studies were excluded because 
they did not meet the eligibility criteria based 
on their titles and abstracts. After reviewing 
the full texts, 11 studies were finally included. 
For studies containing insulin consumption, 
1132 eligible studies were identified by key-
word search. After excluding duplicates 
(N=750) and studies without eligibility crite-
ria based on their titles, abstracts and full text 
(N=285), 5 studies were finally included. 
The characteristics of each included stud-
ies and participants in association with met-
formin and insulin treatments are presented in 
Table 1 and 2. Of the 11 studies presented 
based on metformin treatment (Table 1), 8 
studies were retrospective cohort, 2 studies 
were case-control and only one study was a 
cross-sectional. In cohort studies, of the 
51002 patients with type 2 diabetes, 5512 
were assigned to the metformin group and 
45490 of patients were assigned to non-met-
formin group. A total of 983 subjects in case-
control studies, were randomly allocated to 
case (n=361) and control (n=622) groups. The 
mean age of patients who consumed metfor-
min ranged from 60 to 71 years. Three studies 
reported both total and advanced adenoma, 4 
studies were only about adenoma recurrence 
and 4 studies just reported total adenoma.
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Figure 1: Flow chart of article selection process 
Potentially relevant articles from databases 
(N= 652)
(Pub Med= 178, Web of Science= 208, Cochrane library= 72, 
Scopus= 194)
(N=1132)
(Pub Med= 848, Web of Science= 212, Cochrane library= 10, 
Scopus= 62) 
Exclude: 750 duplicates title
382 abstracts evaluated
Exclude: 285 based on 
eligibility criteria on the titles/
abstracts
Excluded:
32 article did not report 
diabetes
58 articles reported just 
colorectal cancer
2 articles have no desirable 
outcomes
97 full text studies reviewed
Insulin metformin
Articles included in our meta-
analysis (n=5)
365 abstracts evaluated
92 full text studies reviewed
Articles included in our meta-
analysis  (n=11)
Exclude: 287 duplicates title
Exclude: 273 based on 
eligibility criteria on the titles/
abstracts
Excluded:
22 article did not report 
diabetes
56 articles reported just 
colorectal cancer
3 articles have no desirable 
outcomes
Searched keywords: metformin, insulin, adenoma, colonic polyps, colorectal adenoma, adenomatous 
polyps, diabetes mellitus, Type 2 
 
Table 1: Characteristic of studies included in the meta-analysis (Metformin) 
Author Coun-
try 
Study 
type 
Sam-
ple 
size 
(N) 
Category 
of  
exposure 
insulin 
(N) 
Mean 
age 
Outcome Adjusted  
variable 
Kim et al. 
(2015) 
Korea Retro-
spective 
cohort 
240 151 62.2 Total ade-
noma, non-
advanced 
adenoma, 
advanced 
adenoma 
Age, gender, 
BMI, smoking 
status, use of 
aspirin and al-
cohol 
Kanadiya 
et al. 
(2013) 
USA Retro-
spective 
cross-
sectional 
405 148 60.63 Colorectal 
adenoma 
Age, gender, 
smoking sta-
tus, use of al-
cohol 
Cho et 
al. (2014) 
Korea Retro-
spective 
cohort 
3105 912 62 Adenoma, 
polyp, 
advanced 
adenoma 
Age, gender, 
BMI, triglycer-
ide, HbA1c, 
duration of 
DM, smoking 
status, use of 
aspirin and 
stain 
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Author Coun-
try 
Study 
type 
Sam-
ple 
size 
(N) 
Category 
of  
exposure 
insulin 
(N) 
Mean 
age 
Outcome Adjusted  
variable 
Jain et 
al. (2016) 
USA Retro-
spective 
cohort 
339 211 60 Adenoma,  
advanced 
adenoma 
Age, sex, BMI 
Eddi et 
al. (2012) 
USA Retro-
spective 
case-con-
trol 
783 NA 71 Colorectal 
adenoma 
Age, sex, 
smoking sta-
tus, history of 
CRC, aspirin 
use 
Lewis et 
al. (2007) 
USA Retro-
spective 
cohort 
44169 3410 66 Colorectal 
adenoma 
Age, sex, BMI, 
diabetes dura-
tion, baseline 
diabetes treat-
ment, rental 
function 
Chung et 
al. (2008) 
Korea Retro-
spective 
case-con-
trol 
200 79 66.5 Colorectal 
adenoma 
Age, gender, 
BMI, duration 
of DM, serum 
levels of 
HbA1c and li-
pids, use of in-
sulin and aspi-
rin 
Lee et al. 
(2012) 
Korea Retro-
spective 
cohort 
240 114 61.9 Recurrent to-
tal  
adenoma 
and  
advanced 
adenoma 
Age, gender, 
BMI, stage of 
cancer, family 
history of 
CRC, follow-
up duration, 
No. of total co-
lonoscopies, 
interval to first 
follow up co-
lonoscopy, No. 
of baseline 
CRA, treat-
ment modality, 
use of aspirin, 
insulin and thi-
azolidinedi-
ones 
Marks et 
al. (2015) 
USA Retro-
spective 
cohort 
2412 457 69 Recurrent 
adenoma 
NA 
Han et al. 
(2017) 
Korea Retro-
spective 
cohort 
257 106 NA Recurrent 
adenoma, re-
current total 
NA 
Shin et 
al. (2013) 
Korea Retro-
spective 
cohort 
240 151 60 Adenoma 
and  
advanced 
adenoma 
NA 
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Table 2: Characteristic of studies included in the meta-analysis (insulin) 
Author Coun-
try 
Study 
type 
Sam-
ple 
size 
(N) 
Category 
of  
exposure 
insulin 
(N) 
Mean 
age 
Out-
come 
Adjusted  
variable 
Chung et 
al. (2008) 
Korea Retro-
spective 
case-con-
trol 
200 38 66.5 Colo-
rectal 
ade-
noma 
Age, gender, BMI, 
duration of DM, se-
rum levels of HbA1c 
and lipids, use of in-
sulin and aspirin 
Jain et al. 
(2016) 
USA Retro-
spective 
cross-
sectional 
339 88 61.6 Colo-
rectal 
ade-
noma 
Age, sex, BMI 
Eddi et 
al. (2012) 
Korea Retro-
spective 
case-con-
trol 
784 912 71 Colo-
rectal 
ade-
noma 
Age, sex, smoking 
status, history of 
CRC, aspirin use 
Dash et 
al. (2013) 
USA Retro-
spective 
case-con-
trol 
486 99 54.6 Colo-
rectal 
ade-
noma 
Age, educational sta-
tus, BMI (weight 
(kg)/height (m)2), 
physical activity, 
family history of colo-
rectal cancer in a 
first-degree relative, 
menopausal status, 
smoking status, alco-
hol intake, total en-
ergy intake, red meat 
intake, fruit and veg-
etable intake, and 
regular aspirin use 
Wong et 
al. (2012) 
USA Retro-
spective 
case-con-
trol 
869 165 64.4 Colo-
rectal 
ade-
noma, 
ad-
vanced 
ade-
noma 
Age and sex 
 
 
Of the 5 study presented for insulin use (Table 
2), all studies were case-control and random-
ized assigned to case (n=1333) and control 
(n=1345) groups. The mean age of insulin re-
cipient patients ranged from 54.6 to 71. 
 
Metformin therapy  
Figure 2 shows the summary ORs of total 
adenoma incidence associated with metfor-
min treatment for T2DM patients according to 
the 7 studies. Significant heterogeneity was 
found across the individual studies which en-
rolled in the meta-analysis (I2=72.5 %, 
p=0.001). Therefore, the effect size was 
pooled using the random-effects model. The 
metformin use was not significantly associ-
ated with reduced incidence of total adenoma 
among T2DM patients (OR=0.86, 95 % 
CI=0.66 to 1.12; p=0.274).The results of 
Bayesian hierarchical modeling were gener-
ally similar to those obtained using the tradi-
tional meta-analysis. The Bayesian credible 
intervals (CrI) were reasonably wider than the 
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traditional confidence intervals (CI), 
(OR=0.89, 95 % CrI=0.65 to 1.14), as they 
accounted for additional variability. Also the 
risk of recurrence adenoma was not signifi-
cantly lower among metformin users than 
controls (non-metformin users) pooled ORs 
(95 % CI) was 0.89 (0.76-1.04). Furthermore, 
the heterogeneity between 4 studies based on 
recurrent adenoma outcome was not signifi-
cant (I2=55.5 %, p=0.08) then, the effect size 
was pooled using the fixed-effects model. 
(Figure 3). 
The small number of studies on advanced 
adenoma leads to Bayesian meta-analysis. 
The significantly reduced advanced adenoma 
polyps was found in diabetes treated with 
metformin use (Figure 4), compared with 
other treatments according to Markov chain 
Monte Carlo (MCMC) Bayesian approach 
(OR=0.55, 95 % CrI=0.38 to 0.77). The non-
significant heterogeneity was found between 
these three studies (I2=59.7 %, p=0.08). The 
result of both traditional and Bayesian ap-
proaches is shown in Table 3. 
For the Bayesian hierarchical modeling, 
we used several different prior distributions 
for parameters. The results showed that 
changing the form of supposed prior distribu-
tion had a minimal effect on pooled estima-
tion. The results using N (0,105) prior for 
mean OR and Gamma distribution for be-
tween study variance are presented in Table 3. 
 
Total adenoma 
Figure 2: Forest plot of odds ratio of metformin on risk of Total adenoma, I2=72.5 %, Egger’s test p-
value=0.048 
 
Recurrent adenoma 
Figure 3: Forest plot of odds ratio of metformin on risk of Recurrent adenoma, I2=55.5 %, Egger’s test 
p-value=0.152 
2013
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Advanced adenoma 
 
Figure 4: Forest plot of odds ratio of Metformin on risk of Advanced adenoma, I2=59.7 %, Egger’s test 
p-value=0.816 
 
 
Table 3: Mean effect sizes (OR) and corresponding statistics for a classical and Bayesian meta-analysis 
Treatment Outcome Classical analysis1 Bayesian analysis2 
Metformin 
therapy 
mean CI3 P >࢞૛4 mean median CRI5 
Total  
adenoma 
0.86 0.66-1.12 0.274 0.89 0.88 0.65-1.14 
Advanced  
adenoma 
0.51 0.41-0.63 < 0.001 0.55 0.54 0.38-0.77 
Recurrent  
adenoma 
0.89 0.76-1.04 0.152 0.68 0.66 0.24-1.45 
Insulin 
therapy 
Total  
adenoma 
1.43 1.15-1.78 0.002 1.46 1.44 1.09-1.96 
1 Based on random-effect model for total adenoma outcome and fixed-effect model for advanced and recurrent adenoma 
2 Assuming priors (	ߤ ൎ ܰሾ0, 10ହሿ	and	ߪିଶ ൎ ܩሾ0.001, 10ଷሿ i.e. (normal for mean and gamma for the inverse of among-study vari-
ance) for total adenoma outcome and Bayesian fixed-effect model for advanced and recurrent adenoma and insulin therapy 
3 CI: 95 % confidence interval 
4 Test for the hypothesis that mean effect size = 1 
5 CRI: 95 % credibility interval 
 
 
Egger's linear regression test was applied to 
assess bias in the publication of three out-
comes. The results revealed that there were no 
statistical evidence of publication bias using 
Egger's linear regression tests for advanced 
adenoma (P =0.816), and adenoma recurrence 
(P=0.152). For total adenoma, in order to 
quantify the amount of bias in the publication 
(P =0.048) the modification of the final meta-
analysis results according to “trim and fill” 
method did not differ from the results of the 
Classic meta-analysis (summary estimate of 
OR (95 % CI)). 
The summary ORs of meta-analysis 
(OR=1.43, 95 % CI=1.15 to 1.78; P=0.002) 
revealed that there was a significant positive 
association between colorectal adenoma inci-
dence and insulin intake between T2DM pa-
tients according to the 5 including studies 
(Figure 5). Then the insulin recipient patients 
had a risk of colorectal adenoma compared 
with those who did not. 
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Insulin therapy 
 
Figure 5: Forest plot of odds ratio of insulin therapy on risk of Colorectal adenoma, I2=0.0 %, Egger’s 
test p-value=0. 207 
 
 
The significant heterogeneity was not 
identified (I2=0.0 %, p=0.435) in related 
meta-analysis. Therefore, the effect size 
pooled using the fixed- effects model. The re-
sults of Bayesian hierarchical modeling was 
inconsistent with the result of the traditional 
meta-analysis (OR=1.46, 95 % CrI=1.09 to 
1.96) (Table 3). Also the result of the Egger's 
linear regression indicated no publication bias 
(P=0.207). 
 
Subgroup analysis 
We conducted the subgroup analysis 
based on the study location, age of the pa-
tients and the study design (Table 4). The re-
sults of the subgroup analysis showed that in 
Korean studies, metformin therapy between 
T2DM patients significantly decreased the 
adenoma risk, totally. However, no signifi-
cant relationship was found between studies 
from USA. This may be due to the dietary 
habits or lifestyle between these two areas. In 
an age-stratified subgroup analysis, the results 
demonstrated that the risk of total adenoma in 
patients whose age ≤ 65 years old in metfor-
min group, was significantly lower than those 
whose age ≥ 65 years old (the annual risk of 
adenoma progression in patients whose age 
was ≥ 65 years old was 17 %).  
This may be for the age as a risk factor of 
colon polyps, especially in diabetic patients. 
The results of subgroup analyses based on the 
study design showed that there was no differ-
ence between cohort and case-control study 
design. 
 
 
 
Table 4: Subgroup analysis of relationship between metformin therapy and risk of total adenoma 
Subgroup  No. of 
studies 
Sample 
size 
Test of Relationship Test of Heterogeneity 
OR (95 %CI) P value X2 I2 P value 
Overall 7 49241 0.85 (0.65-1.12) 0.243 22.59 73.4 % 0.001 
Study location        
  Korea  
  USA 
3 
4 
3545 
45696 
0.75 (0.59-0.96 ) 
0.92 (0.65-1.31) 
0.02 
0.644 
0.23 
11.98 
0.0 % 
75 % 
0.891 
0.007 
Age of  
patients 
       
< 65 (years) 
> 65 (years) 
4 
3 
4089 
45152 
0.71 (0.57-0.87) 
1.17 (1.07-1.26) 
0.001 
< 0.001
1.56 
1.72 
0.0 % 
0.0 % 
0.668 
0.424 
Study type        
  Cohort  
  Case-control 
4 
3 
1388 
47853 
0.89 (0.64-1.23) 
0.80 (0.60-1.08) 
0.484 
0.148 
12.71 
5.58 
76.4 % 
64.2 % 
0.005 
0.06 
2012 
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DISCUSSION 
This meta-analysis sought to identify 
whether T2DM with and without metformin 
intake history have different risk in order to 
colorectal adenoma, using both conventional 
and Bayesian meta-analyses. Compared to 
traditional meta-analyses, we used also the 
Bayesian approach that takes into account all 
sources of variation and reflects these varia-
tions in the pooled result. The main results of 
this meta-analysis of 11 observational studies 
on the metformin use and risk of colorectal 
adenoma were three fold. First, analysis pro-
pose that metformin intake will significantly 
decrease the risk of advanced adenoma (OR= 
0.51). Second, the risk of total adenoma is not 
associated with metformin use between type 
2 diabetes (OR= 0.86) and third, results for 
the pooled ORs indicate that, there was no sta-
tistical association between metformin intake 
in diabetic patients and adenoma recurrence 
(OR= 0.89).In the subgroup analyses, after 
stratifying studies by location, we showed 
that metformin therapy was associated with a 
significant reduction in colorectal adenoma 
risk in Asian population, while no significant 
association was found in North Americans. 
This can be explained by dietary habits and/or 
other cultural and behavioural differences. 
For example, red meat and milk products, as 
well-known colorectal adenoma risks, are 
more popular in western countries (Aune et 
al., 2013; Karagas et al., 1998). Another sub-
group analysis showed that in people younger 
than 65 years, metformin intake significantly 
reduced their risk. When studies were strati-
fied by their designs no significant differences 
were observed. Previous studies have shown 
the protective effect of metformin on CRC 
(Liu et al., 2017) and other cancers such as 
prostate and lung (Kourelis and Siegel, 2012). 
It has been proposed that metformin can de-
crease the risk of colorectal adenoma by 
24 %, but in our analysis we showed that met-
formin has no effect on primary adenoma risk 
which we believed in previous meta-analysis 
patients without diabetes have been included 
(Ford et al., 2012) which may interfere with 
results. Metformin may have anti-cancer ef-
fects through direct (insulin-independent) and 
indirect (insulin-dependent) mechanisms. As 
insulin resistance, hyperinsulinemia and hy-
perglycemia are risk factors of cancers (Yang 
et al., 2004), so the data in patients with dia-
betes should not merge with non-diabetes. 
However the efficacy of metformin in reduc-
ing advanced adenoma was similar to another 
analysis (Ford et al., 2012). These results sug-
gest that metformin may provide a greater 
protective effect against pre-neoplastic le-
sions than against adenoma itself.  
We also provided some evidence that met-
formin may not have beneficial effects against 
recurrence colorectal adenoma. The present 
study is an analysis based on the epidemiolog-
ical studies which included large-scale and 
long-term follow-up results. Insulin signifi-
cantly increases the risk of colorectal ade-
noma in T2DM patients (OR:1.43), however 
in this analysis due to lack of data we could 
not report data on stratified analysis by dura-
tion of insulin use duration of DM or age. 
In conclusion, our meta-analysis indicates 
that metformin is associated with a reduction 
in risk of colorectal adenoma incidence in in-
dividuals with T2DM, compared with insulin 
treatment which significantly increases the 
risk of colon adenoma. So similar to CRC, 
DM medication may affect the risk of CRA. 
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